Comment on: "Clinical Pharmacokinetics of Atypical Antipsychotics: An Update"
- PMID: 31292862
- PMCID: PMC6717184
- DOI: 10.1007/s40262-019-00795-9
Comment on: "Clinical Pharmacokinetics of Atypical Antipsychotics: An Update"
Conflict of interest statement
Antonia Periclou and Todd Riccobene are employees of Allergan plc. and Margit Kapás and István Laszlovszky are employees of Gedeon Richter Plc.
Comment in
-
Reply to Periclou et al.: "Clinical Pharmacokinetics of Atypical Antipsychotics: An Update".Clin Pharmacokinet. 2019 Sep;58(9):1217-1218. doi: 10.1007/s40262-019-00796-8. Clin Pharmacokinet. 2019. PMID: 31292863 No abstract available.
Comment on
-
Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.Clin Pharmacokinet. 2018 Dec;57(12):1493-1528. doi: 10.1007/s40262-018-0664-3. Clin Pharmacokinet. 2018. PMID: 29915922 Review.
References
-
- Allergan. VRAYLAR® (cariprazine). Full prescribing information. Allergan; 2019.
-
- European Medicines Agency. Reagila product information; 2019. https://www.ema.europa.eu/en/documents/product-information/reagila-epar-.... Accessed 26 June 2019.
-
- Carrothers T, Willavize S, Jaworowicz D, Passarell J, Periclou A, Ghahramani P, et al. Relationship of cariprazine plasma concentration to efficacy and safety in patients with schizophrenia or bipolar mania [poster]. American Psychiatric Association (APA) Annual Meeting; 14–18 May 2016; Atlanta.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
